Goutham Sunny: Key Insights on Therapeutic Cancer Vaccines
Goutham Sunny, Assistant Professor at The Gujarat Cancer and Research Institute, shared a post on X about recent article published in Nature by Kun Peng and colleagues:
“Therapeutic Cancer Vaccines: Revitalized and Ready for Precision Immunotherapy
This review explores the renewed promise of therapeutic cancer vaccines, highlighting advancements in antigen selection, vaccine platforms, and combinatorial strategies.
Key Insights:
– Target Antigens:
• Tumor-associated antigens
• Viral oncoproteins
• Neoantigens
• Cryptic antigens
→ Selected based on immunogenicity and therapeutic potential
– Vaccine Platforms Evolution:
• From peptide-based to mRNA vectors
• Innovations enhance antigen delivery and adjuvant efficacy to overcome immune tolerance
– Combinatorial Strategies:
• Vaccines paired with checkpoint inhibitors, cytokine therapies, or other immunomodulators to boost efficacy
Remaining Challenges:
– Improving T-cell activation and durability of response
– Overcoming tumor-induced immune suppression
– Translating preclinical success into clinical benefit
Conclusion: Cancer vaccines are undergoing a renaissance, driven by precision antigen targeting and next-gen delivery systems. Integration with other immunotherapies may unlock their full potential in modern oncology.”
Title: Eliciting antitumor immunity via therapeutic cancer vaccines
Authors: Kun Peng, Xiaoxue Zhao, Yang-Xin Fu, Yong Liang
More posts featuring Goutham Sunny on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023